Phase 2, Single-arm, Open-label, Study of Loncastuximab Tesirine in Combination With Rituximab in Patients With Relapsed or Refractory Follicular Lymphoma
Latest Information Update: 10 May 2024
At a glance
- Drugs Loncastuximab tesirine (Primary) ; Rituximab (Primary) ; Rituximab (Primary)
- Indications Follicular lymphoma
- Focus Therapeutic Use
- 06 May 2024 According to an ADC Therapeutics media release, updates are anticipated at medical meetings in 2024/2025.
- 13 Mar 2024 According to an ADC Therapeutics media release, the study is being expanded to 100 patients in a multicenter clinical trial. Updates are expected at medical meetings.
- 12 Dec 2023 Results (n=26) of pre-specified initial analysis from this study in FL patients presented at the 65th American Society of Hematology Annual Meeting and Exposition